Long Term Care Journal
Friday, May 4, 2018
FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer - FDA Press Releases
FDA approves Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer
from Food and Drug Administration--Press Releases https://ift.tt/2rkL7fy
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment